As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility
The inspection is now closed, and no regulatory action has been recommended
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
The showcase, running March 27–31, puts a spotlight on everything from fine lines to daily sun protection
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN
Subscribe To Our Newsletter & Stay Updated
